These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18805577)

  • 1. Toward experimental assessment of receptor occupancy: TGN1412 revisited.
    Waibler Z; Sender LY; Kamp C; Müller-Berghaus J; Liedert B; Schneider CK; Löwer J; Kalinke U
    J Allergy Clin Immunol; 2008 Nov; 122(5):890-2. PubMed ID: 18805577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.
    Mehrishi JN; Szabó M; Bakács T
    Vaccine; 2007 May; 25(18):3517-23. PubMed ID: 17397974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD28 superagonists: what makes the difference in humans?
    Schraven B; Kalinke U
    Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
    Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
    Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
    Suntharalingam G; Perry MR; Ward S; Brett SJ; Castello-Cortes A; Brunner MD; Panoskaltsis N
    N Engl J Med; 2006 Sep; 355(10):1018-28. PubMed ID: 16908486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF; Sparks SS; Schell K; Shibayama S; McDanal CB; Fang L; Adkison KK; Shachoy-Clark A; Piscitelli SC
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
    Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
    Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.
    Beyersdorf N; Hanke T; Kerkau T; Hünig T
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv91-5. PubMed ID: 16239397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of T-cell differentiation by CD2 and CD28 accessory molecules.
    de Jong R; Stokkers P; Lamme E; Kool JM; Borst F; Brouwer M; Miedema F; van Lier RA
    Immunology; 1991 Oct; 74(2):175-82. PubMed ID: 1684171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
    Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
    J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.
    Beyersdorf N; Gaupp S; Balbach K; Schmidt J; Toyka KV; Lin CH; Hanke T; Hünig T; Kerkau T; Gold R
    J Exp Med; 2005 Aug; 202(3):445-55. PubMed ID: 16061730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Learning from the TGN1412 trial.
    Goodyear M
    BMJ; 2006 Mar; 332(7543):677-8. PubMed ID: 16554332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials.
    Nada A; Somberg J
    Am J Ther; 2007; 14(6):594-604. PubMed ID: 18090886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.